Cystic fibrosis drugs lumacaftor and ivacaftor, which are ineffective in patients with a certain genetic mutation, show promise when prescribed as a duo, reports Medscape.
Together, however, lumacaftor with ivacaftor resulted in improved lung function and reduced pulmonary exacerbation rates in patients with CF who were at least 12 years old and homozygous for the F508del-CFTR mutation, supporting the approval of this combination for the treatment of this patient population, researchers note in The Lancet Respiratory Medicine, online December 20.
Read more at www.medscape.com
